Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa

NCT03923725 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03923725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03923725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa
Lead sponsor
University of Oxford
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2020
Completion date
March 15, 2024
Enrollment
2,583 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum malaria (uncomplicated)